Loading...

Poxel S.A.

POXEL.PAEURONEXT
Healthcare
Biotechnology
0.56
0.007(1.27%)

Poxel S.A. (POXEL.PA) Stock Competitors & Peer Comparison

See (POXEL.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
POXEL.PA€0.56+1.27%30.1M-1.40-€0.40N/A
UCB.BR€185.40+3.66%35.2B33.71€5.49+0.65%
ARGX.BR€523.20+2.23%31.5B36.85€13.96N/A
TUB.BR€146.00+2.82%6.5B72.67€2.02+0.61%
ABVX.PA€61.80+8.42%3.8B-20.47-€2.95N/A
GLPG.AS€28.94+1.69%1.9B-6.41-€4.38N/A
GTBP.PA€280.50+0.00%626.7M-4.10-€68.39N/A
PHARM.AS€0.85-2.47%581M-42.40-€0.02N/A
MEDCL.PA€17.40+0.87%570.3M-15.82-€1.09N/A
VLA.PA€3.28+1.36%556.8M-5.85-€0.56N/A
Showing 1 to 10 of 69 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

POXEL.PA vs UCB.BR Comparison July 2025

POXEL.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POXEL.PA stands at 30.1M. In comparison, UCB.BR has a market cap of 35.2B. Regarding current trading prices, POXEL.PA is priced at €0.56, while UCB.BR trades at €185.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POXEL.PA currently has a P/E ratio of -1.40, whereas UCB.BR's P/E ratio is 33.71. In terms of profitability, POXEL.PA's ROE is +0.32%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, POXEL.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for POXEL.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;